glp-1-receptoragonister Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 for Diabetes vs GLP-1

doi: 10.1016/S0140-6736(22)02076-1 73 Rivera-MartnezWMeja-CardonaASalazar-SolarteAAristizabal-ColoradoDGarces-VillabonLPinillos-SeniorOet al

As previously mentioned, the metabolic rate remains low after significant weight loss and appears to remain low even with weight regain

MPTP, MPP+ and mitochondrial function

For that reason, dose adjustments are often considered within a broader metabolic context rather than as isolated dosing tactics

There were no serious or severe adverse events (AEs) reported, nor discontinuations due to AEs (Table S10)

While these medications work through different mechanismssemaglutide via incretin pathways and levothyroxine through thyroid hormone replacementunderstanding their potential interactions is essential for safe, effective treatment